1976 - The Company was incorporated in December, in the name of J.B.
Mody Chemicals and Pharmaceuticals Ltd. Later the name was
changed to J.B. Chemical and Pharmaceuticals Ltd. and a fresh
Certificate of Incorporation upon change of name was issued on
21st August, 1985 by the Registrar of Companies, Maharashtra at
- J.B. Chemicals and Pharmaceuticals Ltd. is the flagship of the
'Unique' group of companies. The Company was founded by Mr. J.B.
Mody along with his two brothers, Mr. D.B. Mody and Mr. S.B.
Mody. It is engaged in the business of manufacturing bulk
drugs, intermediates, formulations, ayurvedic and herbal
- The Company's manufacturing facilities are situated at Thane,
Belapur, Ankleshwar, Panoli and Daman.
1992 - The Company has commisioned its Soft Gelatine Capsules project at
Panoli in Gujarat.
1993 - The Company issued 20,17,500 No. of Equity Shares of Rs. 10/-
each as fully paid up bonus shares to the shareholders in the
ratio of one bonus share for every two Equity Shares held by
capitalising a sum of Rs. 2,01,75,000/- from the Free Reserves of
1994 - The company allotted 20,17,500 No. of equity shares as fully paid
bonus shares on December 1, 1993 by capitalisation of reserves to
the tune of Rs. 201.75 lakhs.
1996 - The Company during the past year has introduced many new
formulations in the local market. It has also increased its Bulk
Drugs activity due to its R & D work and is able to increase its
exports of Bulk Drug and formulations to various countries.
1998 - The company has launched a slew of new drugs including products
for vaginitis, gingivitis, periodontitis, pelvic inflammatory
diseases and diarrhoea. Besides, it has also forged a technical
collaboration with Fresenins GmbH, Austria for marketing their
specialty products for chronic constipation, prehepatic and
1999 - J. B. Chemicals and Pharmaceutical Ltd is in talks with US
consulting firms to help it enter the generic market for
metronidazole and ranitidine in the US.
2000 - JB Chemicals and Pharmaceuticals is merging pharma divisions of
two other companies - Unique Pharmaceutical Laboratories (UPL)
and Ifiunik Pharmaceuticals (IPL) - into itself.
2002- JB Chemicals & Pharmaceuticals Ltd has informed that the following changes have taken place in the Directorship of the Company:
1 Dr S Agarwala has resigned as a Director w e f March 08, 2002
2 Mr Bansi S Mehta has resigned as alternate Director to Mr Vishnu D Patel w e f March 08, 2002
3 Dr S Agarwala has been appointed as Alternate Director to Mr Vishnu D Patel w e f March 08, 2002
4 Mr Bansi S Mehta has been appointed as Director in casual vacancy caused due to resignation of Dr S Agarwala w e f March 08, 2002.
-J. B. Chemicals join hands with Neotherapeutics of USA.
-JB Chem & Pharma and Neotherapeutics form JV to manage US Clinical Development, Regulatory Approvals and Marketing for JB Products.
-: JB Chemicals & Pharmaceuticals has closed down its wholly owned subsidiary in Mauritius, which was floated in a bid to enhance its exports to European and other countries.
-JBCPL files its first Abbreviated New Drug Application with the US Food and Drug Administration.
-JBCPL becomes the first Indian Company to receive permission from drugs controllers General of India to market Rantac CD formulations.
-JB Chem team up with White Chemicals for European generics Markets.
-JB Chem appoints Dr Rajen Shah as the whole time Director on the board of the company.
-The Company launches two new therapeutic products Cefjoy and Zudo for treatment of infections and health improvement.
-Jb Chemicals & Pharmaceuticals Ltd. has informed that the equity shares of the company have been delisted by ASE w.e.f December 8, 2003.
-JB Chem bags US FDA approval for Panoli drug unit, Gujarat
- Bags final approval from the United States Food and Drug Administration (US FDA), to manufacture and market ciprofloxacin tablets 250 mg, 500 mg and 750 mg in the US market.
-JB Chemicals launches Magnilek, a MRI Contrast media